Wachler & Associates Health Law BlogRecent RAC Activity
CGI has added a new issue to its approved issues list for Region B:
Outpatient Bevacizumab (Avastin) services: Bevacizumab (Avastin) represents 10mg per unit and should be billed one (1) unit for every 10mg per patient. Claims for J9035 should be submitted so that the billed units represent the administered units, not the total number of milligrams.
HealthDataInsights has posted a new issue to its approved issues list:
Multi-use vial wastage: Herceptin (Trastuzumab). Multi-use vials are not subject to payment for discarded amounts of drug or biological. Per, the manufacturer label, J9355 Injection, Trastuzumab, 10mg (Herceptin) is only supplied in a multi-use vial. Providers should only bill the units associated with the dose administered to the patient.
If you have any questions about RAC approved issues, or need assistance with RAC audits or compliance, please contact an experienced health care attorney at Wachler & Associates at 248-544-0888.